Cidara Therapeutics Inc.

21.56
0.88 (4.23%)
At close: Apr 22, 2025, 11:47 AM

Cidara Therapeutics Statistics

Share Statistics

Cidara Therapeutics has 10.95M shares outstanding. The number of shares has increased by 140.12% in one year.

Shares Outstanding 10.95M
Shares Change (YoY) 140.12%
Shares Change (QoQ) 55.44%
Owned by Institutions (%) 99.99%
Shares Floating 6.82M
Failed to Deliver (FTD) Shares 1.14K
FTD / Avg. Volume 0.83%

Short Selling Information

The latest short interest is 470.34K, so 4.3% of the outstanding shares have been sold short.

Short Interest 470.34K
Short % of Shares Out 4.3%
Short % of Float 4.56%
Short Ratio (days to cover) 2.45

Valuation Ratios

The PE ratio is -1.01 and the forward PE ratio is -1.9. Cidara Therapeutics's PEG ratio is 0.

PE Ratio -1.01
Forward PE -1.9
PS Ratio 133.87
Forward PS 1.5
PB Ratio 1.05
P/FCF Ratio -0.97
PEG Ratio 0
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Cidara Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.25, with a Debt / Equity ratio of 0.02.

Current Ratio 4.25
Quick Ratio 4.25
Debt / Equity 0.02
Debt / EBITDA -0.02
Debt / FCF -0.02
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $33.55K
Profits Per Employee $-4.47M
Employee Count 38
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by 99.9% in the last 52 weeks. The beta is 0.89, so Cidara Therapeutics's price volatility has been higher than the market average.

Beta 0.89
52-Week Price Change 99.9%
50-Day Moving Average 21.4
200-Day Moving Average 16.87
Relative Strength Index (RSI) 53.9
Average Volume (20 Days) 138.24K

Income Statement

In the last 12 months, Cidara Therapeutics had revenue of 1.27M and earned -169.83M in profits. Earnings per share was -26.75.

Revenue 1.27M
Gross Profit -83.61M
Operating Income -176.1M
Net Income -169.83M
EBITDA -176.1M
EBIT -176.1M
Earnings Per Share (EPS) -26.75
Full Income Statement

Balance Sheet

The company has 189.82M in cash and 3.58M in debt, giving a net cash position of 186.25M.

Cash & Cash Equivalents 189.82M
Total Debt 3.58M
Net Cash 186.25M
Retained Earnings -611.26M
Total Assets 214.8M
Working Capital 161.18M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -176.53M and capital expenditures -129K, giving a free cash flow of -176.66M.

Operating Cash Flow -176.53M
Capital Expenditures -129K
Free Cash Flow -176.66M
FCF Per Share -27.82
Full Cash Flow Statement

Margins

Gross margin is -6557.49%, with operating and profit margins of -13811.92% and -13319.76%.

Gross Margin -6557.49%
Operating Margin -13811.92%
Pretax Margin -13356.16%
Profit Margin -13319.76%
EBITDA Margin -13811.92%
EBIT Margin -13811.92%
FCF Margin -13855.84%

Dividends & Yields

CDTX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for CDTX is $35, which is 70.3% higher than the current price. The consensus rating is "Buy".

Price Target $35
Price Target Difference 70.3%
Analyst Consensus Buy
Analyst Count 7
Stock Forecasts

Stock Splits

The last stock split was on Apr 24, 2024. It was a backward split with a ratio of 1:20.

Last Split Date Apr 24, 2024
Split Type backward
Split Ratio 1:20

Scores

Altman Z-Score -1.99
Piotroski F-Score 1